Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 3/20 | 0.37 |
| ▸ | RXRB | P28702 | 1/20 | 0.37 |
| ▸ | RXRG | P48443 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 2/20 | 0.35 |
| ▸ | THRA | P10827 | 2/20 | 0.34 |
| ▸ | THRB | P10828 | 2/20 | 0.34 |
| ▸ | ESR1 | P03372 | 2/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 5/20 | 0.33 |
| ▸ | CNR2 | P34972 | 5/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2149388 | 0.95 | RXRA (0.39) | RXRARXRBRXRGPPARGTHRA | |
| SCHEMBL2150167 | 0.90 | RXRA (0.36) | RXRARXRBRXRGPPARGTHRA | |
| SCHEMBL2232312 | 0.90 | RXRA (0.38) | RXRARXRBRXRGPPARGTHRA | |
| SCHEMBL2235018 | 0.86 | RXRA (0.37) | RXRARXRBRXRGPPARGTHRA | |
| SCHEMBL2149343 | 0.85 | LNPEP (0.43) | RXRARXRBRXRGPPARGTHRA | |
| SCHEMBL2149375 | 0.85 | RXRA (0.38) | RXRARXRBRXRGPPARG | |
| SCHEMBL2232073 | 0.84 | RXRA (0.40) | RXRARXRBRXRGPPARGTHRA | |
| SCHEMBL2235395 | 0.84 | RXRA (0.40) | RXRARXRBRXRGPPARGTHRA | |
| SCHEMBL2166401 | 0.80 | RXRA (0.39) | RXRARXRBRXRGPPARGTHRA | |
| SCHEMBL2150165 | 0.80 | LNPEP (0.38) | RXRARXRBRXRGPPARGLNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2341042-B1 | METHOD FOR PRODUCING OPTICALLY ACTIVE CYCLOPROPANE CARBOXYLIC ACID ESTER COMPOUND, ASYMMETRIC COPPER COMPLEX, AND OPTICALLY ACTIVE SALICYLIDENEAMINOALCOHOL COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2019-03-20 | — | — | EP | disclosed |
| US-8680328-B2 | Method for producing optically active cyclopropane carboxylic acid ester compound, asymmetric copper complex, and optically active salicylideneaminoalcohol compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-03-25 | — | — | US | disclosed |
| US-20110166372-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE CYCLOPROPANE CARBOXYLIC ACID ESTER COMPOUND, ASYMMETRIC COPPER COMPLEX, AND OPTICALLY ACTIVE SALICYLIDENEAMINOALCOHOL COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-07-07 | — | — | US | disclosed |
| EP-2341042-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE CYCLOPROPANE CARBOXYLIC ACID ESTER COMPOUND, ASYMMETRIC COPPER COMPLEX, AND OPTICALLY ACTIVE SALICYLIDENEAMINOALCOHOL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2011-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166372-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE CYCLOPROPANE CARBOXYLIC ACID ESTER COMPOUND, ASYMMETRIC COPPER COMPLEX, AND OPTICALLY ACTIVE SALICYLIDENEAMINOALCOHOL COMPOUND | ALDH18A1, ALDH3A1, DECR1 | RXRA 734/4885RXRB 1164/4885RXRG 1640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.